FFA
ARQT icon

Farther Finance Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Farther Finance Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$23.6K Buy
893
+147
+20% +$3.84K ﹤0.01% 4013
2026
Q2 		$19.7K Buy
746
+394
+112% +$9.18K ﹤0.01% 3991
2026
Q1 		$8.48K Sell
352
-222
-39% -$5.67K ﹤0.01% 4212
2025
Q4 		$16.7K Buy
574
+284
+98% +$7.27K ﹤0.01% 3557
2025
Q3 		$5.47K Buy
290
+217
+297% +$3.42K ﹤0.01% 3719
2025
Q2 		$1.02K Buy
73
+29
+66% +$407 ﹤0.01% 3895
2025
Q1 		$659 Hold
44
– – ﹤0.01% 3726
2024
Q4 		$613 Hold
44
– – ﹤0.01% 3401
2024
Q3 		$409 Buy
44
+14
+47% +$138 ﹤0.01% 3469
2024
Q2 		$287 Sell
30
-249
-89% -$2.25K ﹤0.01% 3410
2024
Q1 		$2.7K Buy
279
+269
+2,690% +$2.01K ﹤0.01% 2365
2023
Q4 		$32 Buy
+10
New +$27 ﹤0.01% 3424

Other funds holding ARQT

PL
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Farther Finance Advisors's ARQT Position: Q3 2026 in Review

Farther Finance Advisors increased its Arcutis Biotherapeutics (ARQT) stake by 20% in Q3 2026, buying an estimated $3.84K and bringing the position to 893 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4013.

Farther Finance Advisors first reported a position in ARQT in Q4 2023 and has held it in 12 quarters since. 10 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Farther Finance Advisors held 893 shares of Arcutis Biotherapeutics worth $23.6K as of Q3 2026.
  • Farther Finance Advisors bought 147 Arcutis Biotherapeutics shares in Q3 2026, an estimated $3.84K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4013 holding.
  • Farther Finance Advisors first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 12 quarters since.
  • 10 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.